Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Immunotherapy"" wg kryterium: Temat


Starter badań:

Tytuł :
Antigen Loss after Targeted Immunotherapy in Hematological Malignancies.
Autorzy :
Zhou T; Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Wang HW; Flow Cytometry Unit, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: .
Pokaż więcej
Źródło :
Clinics in laboratory medicine [Clin Lab Med] 2021 Sep; Vol. 41 (3), pp. 341-357. Date of Electronic Publication: 2021 Jul 02.
Typ publikacji :
Journal Article; Research Support, N.I.H., Intramural; Review
MeSH Terms :
Hematologic Neoplasms*/therapy
Immunotherapy, Adoptive*
Humans ; Immunotherapy ; Tumor Escape
Czasopismo naukowe
Tytuł :
The State of Immunotherapy in Hepatobiliary Cancers.
Autorzy :
Ilyas FZ; College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.; Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.; The James Comprehensive Cancer Center, Columbus, OH 43210, USA.
Beane JD; Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.; The James Comprehensive Cancer Center, Columbus, OH 43210, USA.
Pawlik TM; Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.; The James Comprehensive Cancer Center, Columbus, OH 43210, USA.
Pokaż więcej
Źródło :
Cells [Cells] 2021 Aug 15; Vol. 10 (8). Date of Electronic Publication: 2021 Aug 15.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy*
Biliary Tract Neoplasms/*therapy
Carcinoma, Hepatocellular/*therapy
Liver Neoplasms/*therapy
Antibodies, Bispecific/therapeutic use ; Cancer Vaccines/therapeutic use ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy, Adoptive ; Oncolytic Viruses ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł :
Role of salivary microbiome in IL-10 production and efficacy of sublingual immunotherapy.
Autorzy :
Oka A; Department of Otorhinolaryngology, International University of Health and Welfare Graduate School of Medicine, Narita, Japan.
Kidoguchi M; Department of Otorhinolaryngology Head & Neck Surgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.; Department of Medical Genetics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Kariya S; Departments of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Fujiwara T; Departments of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Yuta A; Yuta Clinic, Tsu, Japan.
Miyashita H; Yuta Clinic, Tsu, Japan.
Higaki T; Departments of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Ogawa Y; Yuta Clinic, Tsu, Japan.
Kanai K; Department Otorhinolaryngology-Head & Neck Surgery, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Makihara SI; Department Otorhinolaryngology-Head & Neck Surgery, Kagawa Rosai Hospital, Marugame, Japan.
Haruna T; Department Otorhinolaryngology, Himeji St. Mary's Hospital, Himeji, Japan.
Kunisawa J; Laboratory of Vaccine Materials, Center for Vaccine and Adjuvant Research, and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan.
Adachi N; Department of Otorhinolaryngology Head & Neck Surgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.; Department of Medical Genetics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Koyama K; Department of Otorhinolaryngology Head & Neck Surgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Ii R; Department of Medical Genetics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Noguchi E; Department of Medical Genetics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Fujieda S; Department of Otorhinolaryngology Head & Neck Surgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Nishizaki K; Departments of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Okano M; Department of Otorhinolaryngology, International University of Health and Welfare Graduate School of Medicine, Narita, Japan.; Departments of Otolaryngology-Head & Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Pokaż więcej
Źródło :
Allergy [Allergy] 2021 Aug; Vol. 76 (8), pp. 2617-2620. Date of Electronic Publication: 2021 May 03.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Microbiota*
Rhinitis, Allergic*
Rhinitis, Allergic, Seasonal*
Sublingual Immunotherapy*
Humans ; Immunotherapy ; Interleukin-10 ; Treatment Outcome
Raport
Tytuł :
Infusion reactions in natural killer cell immunotherapy: a retrospective review.
Autorzy :
Mamo T; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
Williams SM; Department of Pathology and Microbiology, Nebraska Medical Center, Omaha, Nebraska, USA.
Kinney S; Division of Pathology and Laboratory Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Tessier KM; Masonic Cancer Center Biostatistics Core, University of Minnesota, Minneapolis, Minnesota, USA.
DeFor TE; Masonic Cancer Center Biostatistics Core, University of Minnesota, Minneapolis, Minnesota, USA.
Cooley S; Fate Therapeutics, San Diego, California, USA.
Miller JS; Department of Medicine, Division of Hematology, Oncology, and Transplantation, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.
McKenna DH; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address: .
Pokaż więcej
Źródło :
Cytotherapy [Cytotherapy] 2021 Jul; Vol. 23 (7), pp. 627-634. Date of Electronic Publication: 2021 May 09.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Immunotherapy*/adverse effects
Killer Cells, Natural*
Humans ; Immunotherapy, Adoptive ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: A comprehensive review.
Autorzy :
Jin KT; Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Du WL; Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.; Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
Lan HR; Department of Breast and Thyroid Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Liu YY; Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Mao CS; Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Du JL; Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
Mou XZ; Clinical Research Institute, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 Jul; Vol. 112 (7), pp. 2592-2606. Date of Electronic Publication: 2021 Jun 05.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Disease Models, Animal*
Immunotherapy*
Xenograft Model Antitumor Assays*
Neoplasms/*therapy
Animals ; Antibodies, Monoclonal/therapeutic use ; Cytokines/metabolism ; Drug Development ; Genetic Engineering ; Graft Rejection/immunology ; Graft vs Host Disease/prevention & control ; Humans ; Immunotherapy, Adoptive/methods ; Intercellular Signaling Peptides and Proteins/metabolism ; Killer Cells, Natural/immunology ; Mice ; Mice, SCID ; Neoplasms/immunology ; Precision Medicine ; Translational Medical Research ; Transplantation, Heterologous
Czasopismo naukowe
Tytuł :
Innate lymphoid cells type 2 in LTP-allergic patients and their modulation during sublingual immunotherapy.
Autorzy :
Palomares F; Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.
Gómez F; Allergy Clinical Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
Bogas G; Allergy Clinical Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
Maggi L; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Cosmi L; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Annunziato F; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Núñez R; Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.
Pérez N; Allergy Clinical Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
Muñoz-Cano R; Allergy Section, Pneumology Department, Institut Clínic Respiratori (ICR), Hospital Clínic de Barcelona, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi iSunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Torres MJ; Allergy Clinical Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.; Medicine Department, Universidad de Málaga-UMA, Málaga, Spain.
Mayorga C; Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.; Allergy Clinical Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
Pokaż więcej
Źródło :
Allergy [Allergy] 2021 Jul; Vol. 76 (7), pp. 2253-2256. Date of Electronic Publication: 2021 Feb 06.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Hypersensitivity*/therapy
Rhinitis, Allergic*
Sublingual Immunotherapy*
Allergens ; Animals ; Humans ; Immunity, Innate ; Immunotherapy ; Lymphocytes ; Pyroglyphidae
Raport
Tytuł :
Differentiation and Regulation of T H Cells: A Balancing Act for Cancer Immunotherapy.
Autorzy :
Basu A; Clinical Science Division, Moffitt Cancer Center, Tampa, FL, United States.
Ramamoorthi G; Clinical Science Division, Moffitt Cancer Center, Tampa, FL, United States.
Albert G; Clinical Science Division, Moffitt Cancer Center, Tampa, FL, United States.
Gallen C; Clinical Science Division, Moffitt Cancer Center, Tampa, FL, United States.
Beyer A; Clinical Science Division, Moffitt Cancer Center, Tampa, FL, United States.
Snyder C; Clinical Science Division, Moffitt Cancer Center, Tampa, FL, United States.
Koski G; Department of Biological Sciences, Kent State University, Kent, OH, United States.
Disis ML; UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, WA, United States.
Czerniecki BJ; Clinical Science Division, Moffitt Cancer Center, Tampa, FL, United States.; Department of Oncological Sciences, University of South Florida, Tampa, FL, United States.; Department of Breast Cancer Program, Moffitt Cancer Center, Tampa, FL, United States.
Kodumudi K; Clinical Science Division, Moffitt Cancer Center, Tampa, FL, United States.; Department of Biological Sciences, Kent State University, Kent, OH, United States.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 May 03; Vol. 12, pp. 669474. Date of Electronic Publication: 2021 May 03 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
MeSH Terms :
Immunotherapy*/adverse effects
Lymphocytes, Tumor-Infiltrating/*immunology
Neoplasms/*therapy
T-Lymphocytes, Cytotoxic/*immunology
T-Lymphocytes, Helper-Inducer/*immunology
Tumor Microenvironment/*immunology
Animals ; Antigens, Neoplasm/metabolism ; Cancer Vaccines/therapeutic use ; Cell Differentiation ; Cytokines/metabolism ; Cytotoxicity, Immunologic ; Humans ; Immunotherapy, Adoptive ; Lymphocyte Activation ; Lymphocytes, Tumor-Infiltrating/metabolism ; Neoplasms/immunology ; Neoplasms/metabolism ; Neoplasms/pathology ; Phenotype ; Signal Transduction ; T-Lymphocytes, Cytotoxic/metabolism ; T-Lymphocytes, Helper-Inducer/metabolism
Czasopismo naukowe
Tytuł :
Exploring novel systemic biomarker approaches in grass-pollen sublingual immunotherapy using omics.
Autorzy :
Barker-Tejeda TC; Facultad de Farmacia, Centro de Metabolómica y Bioanálisis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Madrid, España.; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Bazire R; Servicio de Alergia, Instituto de Investigación Sanitaria Princesa (IP), Hospital Universitario de La Princesa, Madrid, España.; Servicio de Alergia, Hospital Infantil Universitario Niño Jesús, Fundación para la Investigación Biomédica del Hospital Niño Jesús, Madrid, España.
Obeso D; Facultad de Farmacia, Centro de Metabolómica y Bioanálisis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Madrid, España.; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Mera-Berriatua L; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Rosace D; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Vazquez-Cortes S; Servicio de Alergia, Hospital Clínico San Carlos, Universidad Complutense, IdISSC, Madrid, España.
Ramos T; Servicio de Alergia, Instituto de Investigación Sanitaria Princesa (IP), Hospital Universitario de La Princesa, Madrid, España.
Rico MDP; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Chivato T; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Barbas C; Facultad de Farmacia, Centro de Metabolómica y Bioanálisis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Madrid, España.
Villaseñor A; Facultad de Farmacia, Centro de Metabolómica y Bioanálisis (CEMBIO), Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Madrid, España.; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Escribese MM; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Fernández-Rivas M; Servicio de Alergia, Hospital Clínico San Carlos, Universidad Complutense, IdISSC, Madrid, España.
Blanco C; Servicio de Alergia, Instituto de Investigación Sanitaria Princesa (IP), Hospital Universitario de La Princesa, Madrid, España.
Barber D; Facultad de Medicina, Departamento de Ciencias Médicas Básicas, Instituto de Medicina Molecular Aplicada (IMMA), Universidad San Pablo-CEU, CEU Universities, Madrid, España.
Pokaż więcej
Źródło :
Allergy [Allergy] 2021 Apr; Vol. 76 (4), pp. 1199-1212. Date of Electronic Publication: 2020 Sep 22.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Rhinitis, Allergic, Seasonal*/diagnosis
Rhinitis, Allergic, Seasonal*/therapy
Sublingual Immunotherapy*
Allergens ; Biomarkers ; Desensitization, Immunologic ; Double-Blind Method ; Humans ; Immunotherapy ; Poaceae ; Pollen
Czasopismo naukowe
Tytuł :
Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy.
Autorzy :
Chodnicki KD; Massachusetts Eye and Ear, Department of Ophthalmology, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.
Prasad S; Harvard Medical School, Boston, MA, USA.; Brigham and Women's Hospital, Department of Neurology, Boston, MA, USA.
Pokaż więcej
Źródło :
Seminars in ophthalmology [Semin Ophthalmol] 2021 May 19; Vol. 36 (4), pp. 329-334. Date of Electronic Publication: 2021 Mar 10.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy, Adoptive*
Receptors, Chimeric Antigen*
Cell- and Tissue-Based Therapy ; Humans ; Immunotherapy ; Receptors, Antigen, T-Cell/genetics
Czasopismo naukowe
Tytuł :
Immunotherapy of gastric cancer: Past, future perspective and challenges.
Autorzy :
Xie J; Department of Gastroenterology Surgery, Affiliated Hospital of Shaoxing University, Shaoxing 312000, Zhejiang Province, China.
Fu L; Department of Nuclear Medicine, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China.
Jin L; Department of Pathology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China. Electronic address: .
Pokaż więcej
Źródło :
Pathology, research and practice [Pathol Res Pract] 2021 Feb; Vol. 218, pp. 153322. Date of Electronic Publication: 2020 Dec 24.
Typ publikacji :
Historical Article; Journal Article; Review
MeSH Terms :
Immunotherapy*/history
Immunotherapy*/trends
Lymphocytes, Tumor-Infiltrating/*immunology
Stomach Neoplasms/*therapy
T-Lymphocytes, Cytotoxic/*immunology
Tumor Microenvironment/*immunology
Animals ; Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Cancer Vaccines/therapeutic use ; Cytotoxicity, Immunologic ; Diffusion of Innovation ; Forecasting ; History, 20th Century ; History, 21st Century ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy, Adoptive ; Lymphocytes, Tumor-Infiltrating/drug effects ; Lymphocytes, Tumor-Infiltrating/metabolism ; Stomach Neoplasms/immunology ; Stomach Neoplasms/metabolism ; Stomach Neoplasms/pathology ; T-Lymphocytes, Cytotoxic/drug effects ; T-Lymphocytes, Cytotoxic/metabolism ; Tumor Escape
Czasopismo naukowe
Tytuł :
Targeting loss of heterozygosity for cancer-specific immunotherapy.
Autorzy :
Hwang MS; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; HHMI, Chevy Chase, MD 20815.; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Mog BJ; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; HHMI, Chevy Chase, MD 20815.; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21218.
Douglass J; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; HHMI, Chevy Chase, MD 20815.; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Pearlman AH; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; HHMI, Chevy Chase, MD 20815.; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Hsiue EH; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; HHMI, Chevy Chase, MD 20815.; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Paul S; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; HHMI, Chevy Chase, MD 20815.; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
DiNapoli SR; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; HHMI, Chevy Chase, MD 20815.; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
Konig MF; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; HHMI, Chevy Chase, MD 20815.; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224.
Pardoll DM; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287.
Gabelli SB; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Bettegowda C; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Papadopoulos N; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.; Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Vogelstein B; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; HHMI, Chevy Chase, MD 20815.; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287.; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.; Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Zhou S; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287; .; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287.
Kinzler KW; Ludwig Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287; .; Lustgarten Laboratory for Pancreatic Cancer Research, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287.; Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287.; Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2021 Mar 23; Vol. 118 (12).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor*
Immunotherapy*/methods
Loss of Heterozygosity*
Molecular Targeted Therapy*/adverse effects
Molecular Targeted Therapy*/methods
Neoplasms/*etiology
Neoplasms/*therapy
Alleles ; Antigens, Neoplasm/immunology ; Cell- and Tissue-Based Therapy ; HLA Antigens/genetics ; HLA Antigens/immunology ; Humans ; Immunotherapy, Adoptive ; Single-Chain Antibodies/pharmacology ; Single-Chain Antibodies/therapeutic use
Czasopismo naukowe
Tytuł :
Current Immunotherapies for Glioblastoma Multiforme.
Autorzy :
Huang B; Department of Neurosurgery, Beijing Electric Power Hospital, Beijing, China.
Li X; Department of Neurosurgery, Huizhou Third People's Hospital, Guangzhou Medical University, Huizhou, China.
Li Y; Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Guangzhou, China.
Zhang J; Department of Neurosurgery, The First Affiliated Hospital, Jinan University, Guangzhou, China.
Zong Z; Department of Neurosurgery, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, China.
Zhang H; Department of Neurosurgery, Huizhou Third People's Hospital, Guangzhou Medical University, Huizhou, China.; Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Guangzhou, China.; Department of Neurosurgery, Jiujiang Hospital of Traditional Chinese Medicine, Jiujiang, China.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Mar 09; Vol. 11, pp. 603911. Date of Electronic Publication: 2021 Mar 09 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy*
Brain Neoplasms/*therapy
Glioblastoma/*therapy
Animals ; Brain Neoplasms/immunology ; Brain Neoplasms/metabolism ; Cancer Vaccines/therapeutic use ; Glioblastoma/immunology ; Glioblastoma/metabolism ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy, Adoptive ; Molecular Targeted Therapy ; Oncolytic Virotherapy ; Treatment Outcome ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer.
Autorzy :
Kumai T; Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
Mizukoshi E; Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan. Electronic address: .
Hashiba T; Kanazawa Advanced Medical Center, Kanazawa, Japan.
Nakagawa H; Kanazawa Advanced Medical Center, Kanazawa, Japan.
Kitahara M; Kanazawa Advanced Medical Center, Kanazawa, Japan.
Miyashita T; Kanazawa Advanced Medical Center, Kanazawa, Japan.
Mochizuki T; Kanazawa Advanced Medical Center, Kanazawa, Japan.
Goto S; Seta Clinic Group, Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan.
Kamigaki T; Seta Clinic Group, Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan.
Takimoto R; Seta Clinic Group, Department of Next-Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan.
Yamashita T; Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
Sakai Y; Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
Yamashita T; Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
Honda M; Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
Tomita K; Kanazawa Advanced Medical Center, Kanazawa, Japan.
Kaneko S; Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, Kanazawa, Japan.
Pokaż więcej
Źródło :
Cytotherapy [Cytotherapy] 2021 Feb; Vol. 23 (2), pp. 137-145. Date of Electronic Publication: 2020 Sep 06.
Typ publikacji :
Journal Article
MeSH Terms :
Immunotherapy, Adoptive*
Pancreatic Neoplasms*/therapy
CD8-Positive T-Lymphocytes ; Flow Cytometry ; Humans ; Immunotherapy
Czasopismo naukowe
Tytuł :
Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
Autorzy :
Lim CJ; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Nguyen PHD; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Wasser M; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Kumar P; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Lee YH; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Nasir NJM; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore.
Chua C; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Lai L; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Hazirah SN; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Loh JJH; Division of Pathology, Singapore General Hospital, Singapore, Singapore.
Khor LY; Duke-NUS Medical School, Singapore, Singapore.; Division of Pathology, Singapore General Hospital, Singapore, Singapore.
Yeong J; Division of Pathology, Singapore General Hospital, Singapore, Singapore.; Institute of Molecular Cell Biology (IMCB), Agency of Science, Technology and Research (ASTAR), Singapore, Singapore.
Lim TKH; Duke-NUS Medical School, Singapore, Singapore.; Division of Pathology, Singapore General Hospital, Singapore, Singapore.
Low AWX; Department of Urology, Singapore General Hospital, Singapore, Singapore.
Albani S; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Chong TW; Duke-NUS Medical School, Singapore, Singapore.; Department of Urology, Singapore General Hospital, Singapore, Singapore.
Chew V; Translational Immunology Institute (TII), SingHealth-DukeNUS Academic Medical Centre, Singapore, Singapore.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2021 Jan 29; Vol. 11, pp. 615091. Date of Electronic Publication: 2021 Jan 29 (Print Publication: 2020).
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy, Active*
BCG Vaccine/*therapeutic use
Carcinoma, Transitional Cell/*drug therapy
Lymphocyte Subsets/*immunology
Urinary Bladder Neoplasms/*drug therapy
Carcinoma, Transitional Cell/immunology ; Carcinoma, Transitional Cell/therapy ; Chemotaxis ; Drug Resistance, Neoplasm ; Gene Expression Regulation, Neoplastic/drug effects ; High-Throughput Nucleotide Sequencing ; Humans ; Image Cytometry/instrumentation ; Image Cytometry/methods ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy ; Lymphocyte Activation ; Lymphocyte Count ; Lymphocyte Subsets/drug effects ; Programmed Cell Death 1 Receptor/analysis ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Receptors, Antigen, T-Cell/analysis ; Single-Cell Analysis ; T-Lymphocyte Subsets/chemistry ; T-Lymphocyte Subsets/immunology ; Time Factors ; Transcriptome ; Tumor Escape ; Urinary Bladder Neoplasms/immunology ; Urinary Bladder Neoplasms/therapy
Czasopismo naukowe
Tytuł :
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15 February 2019, Doha, Qatar.
Autorzy :
Guerrouahen B; Research Department, Sidra Medicine, Doha, Qatar.
Elnaggar M; Research Department, Sidra Medicine, Doha, Qatar.
Al-Mohannadi A; Research Department, Sidra Medicine, Doha, Qatar.
Kizhakayil D; Research Department, Sidra Medicine, Doha, Qatar.
Bonini C; Experimental Hematology Unit, University Vita-Salute San Raffaele and Hospital San Raffaele Scientific Institute, Milan, Italy.
Benjamin R; Division of Cancer Studies, King's College Hospital, London, United Kingdom.
Brentjens R; Cellular Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Buchholz CJ; Research Unit for Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany.
Casorati G; Experimental Immunology Unit, University Vita-Salute San Raffaele and Hospital San Raffaele Scientific Institute, Milan, Italy.
Ferrone S; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Locke FL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, United States.
Martin F; Pfizer/University of Granada/Andalusian Regional Government, Genomic Medicine Department, Granada, Spain.
Schambach A; Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boson, MA, United States.
Turtle C; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Veys P; Bone Marrow Transplant Unit, Great Ormond Street (GOS) Hospital, and University College London GOS Institute of Child Health, London, United Kingdom.
van der Vliet HJ; Hans van Der Vliet, Department of Medical Oncology, Amsterdam UMC, VU University and Cancer Center, Amsterdam, Netherlands.; Lava Therapeutics, Utrecht, Netherlands.
Maccalli C; Research Department, Sidra Medicine, Doha, Qatar.
Pokaż więcej
Corporate Authors :
EICCI Faculty Group
Źródło :
Frontiers in immunology [Front Immunol] 2021 Jan 14; Vol. 11, pp. 589381. Date of Electronic Publication: 2021 Jan 14 (Print Publication: 2020).
Typ publikacji :
Congress; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunotherapy*
Neoplasms/*therapy
Animals ; Genetic Engineering ; Humans ; Immunotherapy, Adoptive ; Qatar ; Receptors, Chimeric Antigen/immunology ; T-Lymphocytes/immunology
Raport
Tytuł :
NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
Autorzy :
Sanchez CE; Program for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC.
Dowlati EP; Department of Neurosurgery, Georgetown University Hospital, Washington, DC.
Geiger AE; Program for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC.
Chaudhry K; Program for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC.
Tovar MA; School of Medicine and Health Sciences, George Washington University, Washington, DC.
Bollard CM; Program for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC; School of Medicine and Health Sciences, George Washington University, Washington, DC.
Cruz CRY; Program for Cell Enhancement and Technologies for Immunotherapy and Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC; School of Medicine and Health Sciences, George Washington University, Washington, DC. Electronic address: .
Pokaż więcej
Źródło :
Transplantation and cellular therapy [Transplant Cell Ther] 2021 Jan; Vol. 27 (1), pp. 21-35. Date of Electronic Publication: 2020 Sep 29.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy, Adoptive*
Neoplasms*/therapy
Humans ; Immunotherapy ; Killer Cells, Natural ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
[ROLE OF DENDRITIC CELLS IN PROTECTIVE SUBLINGUAL IMMUNOTHERAPY AGAINST ALLERGY].
Autorzy :
Miyanaga N; Division of Immunology, Department of Infectious Diseases, Faculty of Medicine, University of Miyazaki.; Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, University of Miyazaki.
Takagi H; Division of Immunology, Department of Infectious Diseases, Faculty of Medicine, University of Miyazaki.
Tono T; Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, University of Miyazaki.
Sato K; Division of Immunology, Department of Infectious Diseases, Faculty of Medicine, University of Miyazaki.
Pokaż więcej
Źródło :
Arerugi = [Allergy] [Arerugi] 2021; Vol. 70 (8), pp. 931-935.
Typ publikacji :
Journal Article
MeSH Terms :
Hypersensitivity*/therapy
Sublingual Immunotherapy*
Allergens ; Dendritic Cells ; Desensitization, Immunologic ; Humans ; Immunotherapy
Czasopismo naukowe
Tytuł :
CAR T-Cell Therapy in Hematological Malignancies.
Autorzy :
Haslauer T; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.; Department of Biosciences, Paris Lodron University of Salzburg, 5020 Salzburg, Austria.
Greil R; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
Zaborsky N; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
Geisberger R; Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Aug 20; Vol. 22 (16). Date of Electronic Publication: 2021 Aug 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Hematologic Neoplasms/*therapy
Immunotherapy, Adoptive/*methods
Immunotherapy, Adoptive/*trends
Antigens, Neoplasm/immunology ; Hematologic Neoplasms/metabolism ; Hematologic Neoplasms/pathology ; Humans ; Immunotherapy/methods ; Leukemia/immunology ; Leukemia/therapy ; Lymphoma/immunology ; Lymphoma/therapy ; Receptors, Antigen, T-Cell/immunology ; Receptors, Chimeric Antigen/immunology ; T-Lymphocytes/immunology
Czasopismo naukowe
Tytuł :
Improving safety of cancer immunotherapy via delivery technology.
Autorzy :
Hu D; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China.
Zhang W; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China.
Tang J; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China. Electronic address: .
Zhou Z; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China.
Liu X; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China.
Shen Y; Key Laboratory of Biomass Chemical Engineering of Ministry of Education, Center for Bionanoengineering, and College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang, 310027, China.
Pokaż więcej
Źródło :
Biomaterials [Biomaterials] 2021 Jan; Vol. 265, pp. 120407. Date of Electronic Publication: 2020 Sep 20.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Immunotherapy*
Neoplasms*/therapy
Animals ; Autoimmunity ; Immunotherapy, Adoptive ; Technology ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.
Autorzy :
Derlin T; Department of Nuclear Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. .
Schultze-Florey C; Department of Hematology, Hemostasis, Oncology and Stem-Cell Transplantation, Hannover, Germany.
Werner RA; Department of Nuclear Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Möhn N; Department of Neurology, Hannover, Germany.
Skripuletz T; Department of Neurology, Hannover, Germany.
David S; Department of Nephrology, Hannover Medical School, Hannover, Germany.
Beutel G; Department of Hematology, Hemostasis, Oncology and Stem-Cell Transplantation, Hannover, Germany.
Eder M; Department of Hematology, Hemostasis, Oncology and Stem-Cell Transplantation, Hannover, Germany.
Ross TL; Department of Nuclear Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Bengel FM; Department of Nuclear Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Ganser A; Department of Hematology, Hemostasis, Oncology and Stem-Cell Transplantation, Hannover, Germany.
Koenecke C; Department of Hematology, Hemostasis, Oncology and Stem-Cell Transplantation, Hannover, Germany.
Pokaż więcej
Źródło :
Annals of nuclear medicine [Ann Nucl Med] 2021 Jan; Vol. 35 (1), pp. 132-138. Date of Electronic Publication: 2020 Nov 11.
Typ publikacji :
Journal Article
MeSH Terms :
Fluorodeoxyglucose F18*
Immunotherapy, Adoptive*
Positron Emission Tomography Computed Tomography*
Antigens, CD19/*metabolism
Lymphoma, Large B-Cell, Diffuse/*diagnostic imaging
Lymphoma, Large B-Cell, Diffuse/*therapy
Receptors, Chimeric Antigen/*metabolism
Adult ; Female ; Humans ; Immunotherapy ; Lymphoma, Large B-Cell, Diffuse/metabolism ; Male ; Middle Aged ; Recurrence ; Treatment Failure
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies